1. Scrip
  2. >>New Products

Trelegy Approval Boosts GSK's US Respiratory Business But Pressure Remains

 
• By Eleanor Malone

With the FDA approval of Trelegy Ellipta, GlaxoSmithKline will enjoy first-to-market status with a LABA/LAMA/ICS triple combination therapy to treat COPD in the US. However, it faces the challenge of convincing payers.

Conceptual image of green tree shaped like human lungs
Trelegy is the lone COPD triple therapy in the US...for now

GlaxoSmithKline PLC has become the first company to win approval for a triple combination therapy to treat chronic obstructive pulmonary disease (COPD) in the US. The FDA has approved once-daily Trelegy Ellipta two months ahead of its expected user fee date of Nov. 21, 2017, giving it first-to-market advantage in the biggest market for COPD treatments. Trelegy comprises the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting muscarinic antagonist (LAMA) umeclidinium, and the long-acting beta2-adrenergic agonist (LABA) vilanterol dosed once daily in the Ellipta dry powder inhaler,

The impending launch of Trelegy Ellipta, coming after "the confirmed success" of dual therapy Relvar/Breo Ellipta [fluticasone furoate and vilanterol] and the injectable biologic to treat severe asthma Nucala (mepolizumab), led analysts at Natixis to state in a Sept

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Scrip

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.